Catalog No.
DHC36904
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08887
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Sapelizumab, SA-237, SA237, satralizumab-mwg, CAS: 1535963-91-7
Clone ID
Satralizumab
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder, PMID: 31774956
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial, PMID: 32333898
Satralizumab: First Approval, PMID: 32797372
Satralizumab-mwge, PMID: 33091105
Satralizumab, PMID: 33355730
Antibodies to watch in 2020, PMID: 31847708
Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders, PMID: 33246373
Satralizumab in the treatment of neuromyelitis optica spectrum disorder, PMID: 33167776
Correction to: Satralizumab: First Approval, PMID: 32902801
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder, PMID: 33223088
New therapies for neuromyelitis optica spectrum disorder, PMID: 33186537
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects, PMID: 33059216
Antibodies to watch in 2019, PMID: 30516432
Update on neuromyelitis optica spectrum disorder, PMID: 33009077
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder, PMID: 33011853
Emerging drugs for the treatment of neuromyelitis optica, PMID: 32731771
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options, PMID: 30623348
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases, PMID: 32304439
Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy, PMID: 32348222
Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders, PMID: 33729218
Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders, PMID: 33301078
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders, PMID: 32228250
Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options, PMID: 32306778
Lupus and NMOSD: The Blending of Humoral Autoimmunity, PMID: 33123402
Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials, PMID: 32442886
Immune reconstitution therapy in NMOSD, PMID: 33992916
New Therapeutic Landscape in Neuromyelitis Optica, PMID: 33814893
Antibodies to watch in 2018, PMID: 29300693
[Neuromyelitis Optica Spectrum Disorder], PMID: 34006678
Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials, PMID: 33391166
Recent advances in the treatment of neuromyelitis optica spectrum disorders, PMID: 33741809
Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?, PMID: 33777853
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders, PMID: 33419217
Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience, PMID: 33781948
Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder [Internet], PMID: 34165925
Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics, PMID: 33909234
[Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease], PMID: 33783551
Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature, PMID: 33711580
Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials, PMID: 34354581
[A case of neuromyelitis optica associated with pulmonary Mycobacterium avium complex disease], PMID: 34433747
For research use only. Not for human or drug use.
